title: [Hormonal replacement therapy and lipid metabolism in women on hemodialysis with secondary to uremia estrogen deficiency].
abstract: It has been reported that postmenopausal women taking hormonal replacement therapy (HRT) are at reduced risk for cardiovascular disease mainly because of favorable changes in serum LDL- and HDL-cholesterol. However, the therapy is also known to increase hepatic triglyceride production. Cardiovascular events are the leading cause of death in patients on dialysis and lipid abnormalities are common. The aim of the study was to evaluate the influence of HRT on lipid metabolism in premenopausal women undergoing hemodialysis with premature oestrogen withdrawal. 25 hemodialyzed women, aged 37 +/- 9 years (19-44 years) with serum 17 beta-estradiol < 30 pg/ml were divided into: group I (n = 13) treated with transdermal HRT (estradiol with cyclic norethisterone acetate--Estracomb TTS 50/0.25; Novartis), and control group II (n = 12). Before the treatment serum LDL-cholesterol concentrations were increased in 24% and serum triglycerides in 40% of patients, whereas HDL-cholesterol was decreased in 72% of patients. During one year, in group I a noticeable, 15% increase in serum HDL-cholesterol was observed from 0.90 +/- 0.23 to 1.04 +/- 0.19 mmol/l (34.8 +/- 8.8 to 39.8 +/- 7.4 mg/100 ml; p < 0.01). It was parallel to the increase in serum 17 beta-estradiol concentrations (from 20.5 +/- 8.91 to 50.3 +/- 17.20 pg/ml; p < 0.01). Serum LDL-cholesterol and triglycerides did not change significantly. In the control group all those values remained unchanged.
  
  
  CONCLUSIONS
  In hemodialysis women with premature estrogen deficiency the transdermal cyclic HRT leads to the clinically important increase in serum HDL-cholesterol without significant changes in serum triglyceride concentrations and could be beneficial in reducing cardiovascular risk in this population.
authors.affiliation: Katedra i Klinika Chorób Wewnetrznych i Nefrologii AM w Warszawie.
authors.forename: J
authors.initials: J
authors.lastname: Matuszkiewicz-Rowińska
authors.forename: K
authors.initials: K
authors.lastname: Skórzewska
authors.forename: S
authors.initials: S
authors.lastname: Radowicki
authors.forename: A
authors.initials: A
authors.lastname: Sokalski
authors.forename: S
authors.initials: S
authors.lastname: Niemczyk
authors.forename: K
authors.initials: K
authors.lastname: Wardyn
authors.forename: K
authors.initials: K
authors.lastname: Bijak
authors.forename: J
authors.initials: J
authors.lastname: Przedlacki
authors.forename: K
authors.initials: K
authors.lastname: Ostrowski
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000378:metabolism*; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000172:deficiency* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D017697:Premenopause; D006435:Renal Dialysis / Q000379:methods*; D014280:Triglycerides / Q000378:metabolism*; D014511:Uremia / Q000150:complications
chemical_list: D004967:Estrogens; D014280:Triglycerides; D002784:Cholesterol